Maurer T - Search Results

1

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L. Hedegaard J, et al. Among authors: maurer t. Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16. Cancer Cell. 2016. PMID: 27321955 Free article.

2

Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.

Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, Kübler H. Heck MM, et al. Among authors: maurer t. BJU Int. 2012 Dec;110(11 Pt B):E635-40. doi: 10.1111/j.1464-410X.2012.11364.x. Epub 2012 Aug 13. BJU Int. 2012. PMID: 22889368

3

Detection of circulating tumor cells in different stages of prostate cancer.

Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, Heck MM, Andergassen U, Nawroth R, Gschwend JE, Retz M. Thalgott M, et al. Among authors: maurer t. J Cancer Res Clin Oncol. 2013 May;139(5):755-63. doi: 10.1007/s00432-013-1377-5. Epub 2013 Jan 29. J Cancer Res Clin Oncol. 2013. PMID: 23358719

4

Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.

Horn T, Grab J, Schusdziarra J, Schmid S, Maurer T, Nawroth R, Wolf P, Pritsch M, Gschwend JE, Kübler HR, Beckhove P. Horn T, et al. Among authors: maurer t. Int J Cancer. 2013 Nov;133(9):2145-56. doi: 10.1002/ijc.28233. Epub 2013 Jul 11. Int J Cancer. 2013. PMID: 23625723 Free article.

5

The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer.

Horn T, Ladwein B, Maurer T, Redlin J, Seitz AK, Gschwend JE, Retz M, Kübler HR. Horn T, et al. Among authors: maurer t. World J Urol. 2014 Apr;32(2):359-63. doi: 10.1007/s00345-013-1104-5. Epub 2013 May 26. World J Urol. 2014. PMID: 23708699

6

Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent.

Horn T, Schmid SC, Seitz AK, Grab J, Wolf P, Haller B, Retz M, Maurer T, Autenrieth M, Kübler HR, Gschwend JE. Horn T, et al. Among authors: maurer t. World J Urol. 2015 Jun;33(6):813-9. doi: 10.1007/s00345-014-1355-9. Epub 2014 Jul 10. World J Urol. 2015. PMID: 25007992

7

The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.

Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kübler HR, Slotta-Huspenina J. Horn T, et al. Among authors: maurer t. World J Urol. 2016 Feb;34(2):181-7. doi: 10.1007/s00345-015-1615-3. Epub 2015 Jun 9. World J Urol. 2016. PMID: 26055646

8

Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival.

Schmid SC, Zahel T, Haller B, Horn T, Metzger I, Holzapfel K, Seitz AK, Gschwend JE, Retz M, Maurer T. Schmid SC, et al. Among authors: maurer t. World J Urol. 2016 Apr;34(4):569-76. doi: 10.1007/s00345-015-1654-9. Epub 2015 Aug 11. World J Urol. 2016. PMID: 26260193

9

Correlation of tumor-associated macrophages and NK cells with bladder cancer size and T stage in patients with solitary low-grade urothelial carcinoma.

Krpina K, Babarović E, Španjol J, Đorđević G, Maurer T, Jonjić N. Krpina K, et al. Among authors: maurer t. Wien Klin Wochenschr. 2016 Apr;128(7-8):248-52. doi: 10.1007/s00508-015-0907-3. Epub 2015 Dec 11. Wien Klin Wochenschr. 2016. PMID: 26659909

10

Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.

Heck MM, Thaler MA, Schmid SC, Seitz AK, Tauber R, Kübler H, Maurer T, Thalgott M, Hatzichristodoulou G, Höppner M, Nawroth R, Luppa PB, Gschwend JE, Retz M. Heck MM, et al. Among authors: maurer t. BJU Int. 2017 Jan;119(1):30-37. doi: 10.1111/bju.13493. Epub 2016 Apr 27. BJU Int. 2017. PMID: 27037533

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

704 results

Search Page